Evotec Restructuring Aims To Improve Profitability After Transition Year

Core Viewpoint - Evotec SE is initiating a strategic transformation initiative named "Horizon" to reshape its operating model, enhance margins, and position itself for long-term growth in the drug discovery and preclinical development market [1][2]. Group 1: Strategic Transformation - The "Horizon" initiative builds on Evotec's previous "Priority Reset" and strategic roadmap established over the last two years [1]. - The transformation aims to position Evotec for stronger performance through 2027 and set the groundwork for further optimization and scaling towards 2030 [2]. Group 2: Organizational Changes - Evotec plans to simplify its organizational structure and consolidate expertise into new Centers of Excellence to enhance scientific collaboration and innovation [3]. - The company will reduce its global site footprint from 19 locations in 2024 to 10 sites over the next two years, affecting up to 800 positions [3]. Group 3: Financial Impact - The "Horizon" initiative is expected to generate approximately 75 million euros (around $87.3 million) in annual run-rate cost savings by 2027 [5]. - Restructuring-related cash charges are anticipated to be around 100 million euros between 2026 and 2028, along with potential non-cash impairment charges [5]. Group 4: Financial Outlook - Preliminary fiscal 2025 sales are projected at about 788 million euros, with adjusted EBITDA around 41 million euros, both within prior guidance [6]. - For 2026, revenue is expected to be between 700 million and 780 million euros, with adjusted EBITDA ranging from 0 to 40 million euros, indicating a transition year during restructuring [6]. - Long-term projections suggest revenues exceeding 1 billion euros between 2026 and 2030, with adjusted EBITDA margins expected to reach 20% by 2028 [7].